A class of artemisinin derivatives, their preparation methods and applications

Artemisinin derivatives designed by PROTAC technology have significantly improved the cytotoxicity to hematological tumor cells by covalently ligand and solved the existing artemisinin monomer derivatives in cancer cells The problem of low toxicity has achieved effective inhibition and treatment of hematoma cells.

CN115724850BActive Publication Date: 2024-11-19GUIZHOU MEDICAL UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202211561449.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-12-07
Publication Date
2024-11-19
Estimated Expiration
2042-12-07

AI Technical Summary

Technical Problem

Existing artemisinin monomer derivatives have low cytotoxicity and short half-life in cancer cells, making it difficult to effectively inhibit tumor growth, and have poor therapeutic effects on hematoma cells.

Method used

Through PROTAC technology, a class of artemisinin derivatives were designed to degrade tumor-related protein signaling molecules in hematoma cells, which significantly led to the use of the PROTAC technology to degrade tumor-related protein signaling molecules. Improves cytotoxicity.

Benefits of technology

The designed artemisinin derivative has an inhibitory effect on a variety of cancer cells, especially on hematoma cells, with obvious anti-tumor activity. The IC50 value is several times higher than that of the parent compound, and its mechanism is clear, with potential treatment of hematoma. novel drug candidate compounds.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115724850B_ABST
    Figure CN115724850B_ABST
Patent Text Reader

Abstract

The present invention discloses a class of artemisinin derivatives and their preparation methods and applications. The present invention designs and synthesizes a new class of PROTAC degraders based on artemisinin, and the screened compound AR4 has strong cytotoxicity (IC 50 =50.6nM), which is 10 orders of magnitude higher than the parent compound. Finally, through proteomics quantitative analysis, we further verified that ETS1, ZFAND5, and PCLAF are the target proteins of compound AR4. By adopting the above technical scheme, the double artemisinin derivatives designed and synthesized by PROTAC technology in the present invention have inhibitory effects on various cancer cells, and have obvious anti-tumor activity on hematological tumors. They are new double artemisinin derivatives with therapeutic effects on hematological tumors.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of anti-tumor drugs, and in particular to the application of a class of artemisinin derivatives in the preparation of anti-tumor drugs. Background Art

[0002] Artemisinin is a molecule extracted from the sweet wormwood plant Artemisia annua L. Natural sesquiterpene lactone compounds extracted from artemisinin have been used in traditional Chinese medicine for thousands of years to treat fever and chills. In the 1970s, Tu Youyou's research team discovered that artemisinin as an antimalarial drug can effectively kill malaria parasites, saving millions of lives worldwide. In addition, artemisinin is used clinically to treat coughs, colds and diarrhea, as well as to fight bacterial, fungal and viral infections. Not only that, as early as 1995, researchers at the University of Washington discovered that artemisinin can kill certain types of cancer cells. In in vitro experiments, artemisinin demonstrated cytotoxicity to all tested cancer cells. In the past five years, a large number of new studies have also shown that artemisinin and its derivatives can selectively kill a variety of cancer cells. However, monomeric derivatives of artemisinin show relatively low cytotoxicity in cancer cells and have a short half-life in vivo. In recent years, studies have shown that artemisinin dimers are significantly more effective than monomers, and monomers can inhibit tumor growth with activity several orders of magnitude higher than monomers.

[0003] Proteolysis targeting chimeric molecules (PROTAC) are hybrid bifunctional compounds that can recruit target proteins and target protein degrading enzymes. They are composed of a ligand that can recognize the target protein and an E3 ligase ligand. PROTAC molecules can bring POI and E3 ubiquitin ligase close to each other and induce ubiquitination of POI, and then promote POI degradation through the ubiquitin-proteasome degradation system (UPS). This technology has the advantages of wide targeting, good cell permeability, good tissue specificity, high selectivity, high oral bioavailability, and controllability. Summary of the invention

[0004] The purpose of the present invention is to obtain artemisinin derivatives with higher anti-tumor activity and clear mechanism. The present invention uses PROTAC technology to covalently link bisartemisinin to different E3 ubiquitin ligase ligands through different linkers, and designs a class of artemisinin derivatives that can effectively degrade tumor-related protein signaling molecules in hematological tumor cells, show stronger cytotoxicity, and are excellent anti-tumor candidate compounds.

[0005] The present invention is implemented as follows: Taking one of the artemisinin derivatives as an example, the compound has one of the following general formulas:

[0006] ;

[0007] In the formula, n is a natural number, n=1, 2, 3, 4.

[0008] The preparation method of the artemisinin derivatives has the following synthetic route:

[0009] ;

[0010] In the above routes, n is a natural number, n=1, 2, 3, 4.

[0011] The specific synthesis steps are as follows:

[0012] Step 1: Compounds 1 and 2 were dissolved in N,N-dimethylacetamide (DMA), and then N,N-diisopropylethylamine (DIEA) was added. The mixture was refluxed at 90°C for 6 h. The reaction was completed after TLC detection. The reaction solution was washed with water and extracted with ethyl acetate. The ethyl acetate layer was extracted with saturated brine 2-3 times, dried over anhydrous sodium sulfate, and the organic layer was spin-dried and passed through a column to obtain product 3.

[0013] Step 2: Dissolve compound 3 in tetrahydrofuran (THF), add N,N-diisopropylethylamine (DIEA) after 5 minutes, continue the reaction for 10 minutes, keep the sample, add compound 4, react at room temperature for 4 hours, and detect the completion of the reaction by TLC. Dry THF, dissolve it with an appropriate amount of dichloromethane, extract the dichloromethane layer with brine 2-3 times, dry it with anhydrous sodium sulfate, dry the organic layer, and pass it through a column to obtain the product AR1-4;

[0014] The above artemisinin derivatives can be used to prepare anti-tumor drugs.

[0015] Preferably, the tumor is a hematological tumor.

[0016] By adopting the above technical scheme, the artemisinin derivatives designed and synthesized by the PROTAC technology in the present invention have inhibitory effects on various cancer cells and obvious anti-tumor activity on hematological tumors. They are new artemisinin derivatives that have therapeutic effects on hematological tumors.

[0017] Compound AR1-4 13 C-NMR, 1 H-NMR data:

[0018] Compound AR1: 1 H NMR (400 MHz, DMSO-d6) δ 8.36 (d, J = 14.5 Hz, 1H), 7.48(dd, J = 8.4, 7.2 Hz, 1H), 7.07 (d, J = 6.9 Hz, 1H), 6.87 (d, J = 8.5 Hz, 1H), 6.25(t,J = 5.3 Hz, 1H), 5.37 – 5.27 (m, 2H), 4.89 (dd, J = 12.1, 5.4 Hz, 1H), 4.76(dd, J = 9.8, 3.5 Hz, 2H), 4.03 – 3.88 (m, 2H), 3.74 (m, J = 13.4, 8.1, 5.0 Hz,1H), 3.63 (dd, J = 14.2, 9.1 Hz, 1H), 3.55 – 3.36 (m, 4H), 3.28 (q, J = 6.1 Hz,2H), 2.87 (dd, J = 14.5, 3.5 Hz, 1H), 2.75 – 2.69 (m, 1H), 2.66 – 2.55 (m, 2H),2.36 (m, J = 17.8, 13.4, 5.1 Hz, 4H), 2.14 – 2.07 (m, 1H), 2.01 (d, J = 14.5 Hz,2H), 1.89 – 1.81 (m, 3H), 1.62 (m, J = 22.2, 10.2, 6.0 Hz, 10H), 1.51 – 1.36(m, 10H), 1.33 – 1.16 (m, 6H), 0.93 – 0.84 (m, 12H). 1313C NMR (100 MHz, DMSO-d6) δ 172.46, 171.23, 169.51, 168.46, 167.69, 146.91, 136.25, 132.55, 116.68, 111.56, 109.96, 104.36, 104.23, 102.54, 102.30, 87.90, 81.05, 80.96, 66.52, 66.27, 66.18, 52.53, 52.46, 48.93, 47.81, 45.16, 45.11, 44.36, 44.19, 42.64, 38.70, 37.55, 36.44, 36.39, 34.67, 34.56, 33.02, 31.52, 30.80, 30.72, 29.79, 29.40, 29.17, 26.22, 24.75, 24.71, 24.62, 24.55, 22.88, 22.65, 20.46, 13.14, 13.11.

[0019] Compound AR2: 1 1H NMR (400 MHz, DMSO-d6) δ 8.38 (s, 1H), 7.50 – 7.44 (m, 1H), 7.07 (d, J J = 7.1 Hz, 1H), 6.86 (d, J J = 8.6 Hz, 1H), 6.21 (t, J J = 5.4 Hz, 1H), 5.37 – 5.27 (m, 2H), 4.89 (dd, J J = 11.9, 5.4 Hz, 1H), 4.76 (dd, J J = 9.5, 3.3 Hz, 2H), 4.03 – 3.88 (m, 2H), 3.78 – 3.69 (m, 1H), 3.66 – 3.58 (m, 1H), 3.55 – 3.37 (m, 4H), 3.26 (dd, J J = 12.8, 6.6 Hz, 2H), 2.90 – 2.82 (m, 1H), 2.75 (dd, J J = 6.7, 2.7 Hz, 1H), 2.62 (m, J J = 15.4, 9.8, 5.9 Hz, 2H), 2.40 – 2.26 (m, 4H), 2.11 (m, J= 10.2, 3.8 Hz, 1H), 2.05 – 1.97 (m, 2H), 1.91 – 1.81 (m, 3H), 1.72– 1.56 (m, 10H), 1.42 (dd, J = 12.2, 4.2 Hz, 12H), 1.29 – 1.14 (m, 6H), 0.93 –0.82 (m, 12H). 13 C NMR (100 MHz, DMSO-d6) δ 172.77, 171.22, 169.55, 168.48,167.70, 146.99, 136.23, 132.53, 116.72, 111.51, 109.91, 104.35, 104.23,102.54, 102.29, 87.90, 81.06, 80.97, 66.56, 66.34, 66.29, 52.54, 52.48,48.92, 47.86, 45.17, 44.37, 44.20, 42.46, 38.70, 37.56, 36.44, 36.39, 34.68,34.57, 33.35, 31.51, 30.80, 30.73, 29.26, 29.23, 26.84, 26.21, 24.91, 24.75,24.71, 24.61, 24.55, 22.88, 20.46, 13.15, 13.10.

[0020] Compound AR3: 1 H NMR (400 MHz, DMSO-d6) δ 8.27 (s, 1H), 7.48 (m, J = 8.2,7.4 Hz, 1H), 7.07 (d, J = 7.0 Hz, 1H), 6.87 (d, J = 8.5 Hz, 1H), 6.21 (t, J = 5.4Hz, 1H), 5.32 (dd, J = 16.7, 6.9 Hz, 2H), 4.90 (dd, J = 12.0, 5.3 Hz, 1H), 4.76(dd, J= 9.8, 3.3 Hz, 2H), 4.03 – 3.89 (m, 2H), 3.78 – 3.68 (m, 1H), 3.66 –3.56 (m, 1H), 3.54 – 3.38 (m, 4H), 3.25 (dd, J = 12.8, 6.7 Hz, 2H), 2.97 – 2.82(m, 1H), 2.75 – 2.70 (m, 1H), 2.66 – 2.56 (m, 2H), 2.35 (dd, J = 14.8, 9.9 Hz,4H), 2.15 – 2.07 (m, 1H), 2.02 (d, J = 13.5 Hz, 2H), 1.82 (d, J = 24.1 Hz, 3H),1.65 (m, J = 24.1, 13.0, 3.3 Hz, 12H), 1.40 (t, J = 7.3 Hz, 12H), 1.27 – 1.16 (m,6H), 0.94 – 0.84 (m, 12H). 13C NMR (100 MHz, DMSO-d6) δ 172.99, 171.19,169.55, 168.47, 167.72, 147.03, 136.23, 132.53, 116.73, 111.48, 109.88,104.35, 104.22, 102.55, 102.30, 87.91, 81.07, 80.98, 77.46, 77.35, 77.14,76.83, 66.53, 66.33, 52.54, 52.48, 48.92, 47.85, 45.12, 44.37, 44.21, 42.66,38.70, 37.56, 36.44, 36.40, 34.68, 34.57, 33.40, 31.51, 30.81, 30.74, 29.79,29.28, 29.21, 27.01, 26.23, 25.20, 24.75, 24.71, 24.61, 24.55, 22.88, 20.48,13.16, 13.11.

[0021] Compound AR4: 1 H NMR (400 MHz, DMSO-d6) δ 11.12 (s, 1H), 7.56 (m,J = 7.6Hz, 1H), 7.04 (dd, J = 24.7, 7.7 Hz, 2H), 6.51 (t, J = 5.2 Hz, 1H), 5.24 (d, J =8.5 Hz, 2H), 5.03 (dd, J = 12.6, 5.2 Hz, 1H), 4.66 (d, J = 12.9 Hz, 2H), 3.83 –3.74 (m, 2H), 3.44 – 3.36 (m, 6H), 3.27 (d, J = 6.2 Hz, 2H), 2.92 – 2.80 (m,1H), 2.58 (d, J = 18.5 Hz, 1H), 2.31 (dd, J = 21.9, 14.9 Hz, 5H), 2.15 (t, J = 13.6Hz, 2H), 1.98 (t, J = 15.2 Hz, 4H), 1.83 – 1.70 (m, 3H), 1.67 – 1.36 (m, 14H),1.26 (s, 12H), 1.20 – 1.00 (m, 4H), 0.84 (dd, J = 14.0, 7.0 Hz, 12H). 13 C NMR(100 MHz, DMSO-d6) δ 173.43, 172.83, 170.62, 169.46, 167.85, 146.91, 136.84,132.65, 117.67, 110.94, 109.42, 103.90, 103.86, 101.61, 101.29, 87.41, 80.95,80.88, 65.98, 65.54, 52.45, 49.02, 47.53, 44.62, 44.24, 44.09, 42.30, 37.27,37.22, 36.49, 34.61, 33.24, 31.47, 30.88, 30.84, 29.35, 29.29, 29.20, 26.85,26.81, 26.10, 25.39, 24.79, 24.52, 24.43, 22.67, 20.67, 13.24, 13.13. Description of the Drawings

[0022] Figure 1 This is a volcano map obtained by proteomics analysis of the target protein.

[0023] Figure 2 Degraded target proteins were verified by Western Blot DETAILED DESCRIPTION

[0024] In order to enable those skilled in the art to better understand the technical solution of the present invention and implement it, the present invention is further described below in conjunction with specific examples and drawings, but the examples cited are not intended to limit the present invention.

[0025] The ingredients or materials involved in the following methods are all commercially available unless otherwise specified. The relevant experimental methods are all conventional methods in the art unless otherwise specified.

[0026] Example 1: Toxicity of artemisinin derivatives in different cell lines

[0027] The CCK-8 method, which is recognized for large-scale anti-tumor drug screening and cytotoxicity test determination, was used to evaluate the anti-cell proliferation activity of AR1-4 and parent compound 4 against cytotoxic human cancer cell lines RPMI8226 (human multiple myeloma peripheral blood B lymphocytes), RS4;11 (human acute lymphoblastic leukemia cells) and U266 (human myeloma cells); the negative control group was a group without drug addition.

[0028] Cell proliferation inhibition rate = (OD value of negative control group - OD value of drug group) * 100% / OD value of negative control group. IC50 value (in nM) was obtained by GraphPad Prism 5 simulation curve based on the inhibition rate of different concentrations of the compound.

[0029] Table 1. IC50 for cells from three different hematological tumors

[0030] As shown in Table 1, the designed compounds have a strong cytotoxicity in RS4;11 cells, among which compound AR4 reaches 50.6 nM, which is 10 times more toxic than the parent compound. However, as the length of the linker increases, the activity decreases.

[0031] Example 2: Proteomics further analysis of target-related proteins

[0032] This experiment was based on TMT / iTRAQ-labeled quantitative proteomics technology to perform relative quantitative comparison of proteins between compound 4 and AR4 samples, screen differentially expressed proteins, and perform subsequent bioinformatics analysis. The results are as follows: Figure 1 .

[0033] Table 1. IC50 for cells from three different hematological tumors

[0034]

[0035] like Figure 1 As shown, compound AR4 significantly downregulated 9 proteins, among which we screened four tumor-related proteins for further validation

[0036] Example 3: Verification of degradation-related target proteins by Western Blot

[0037] The downregulated proteins associated with tumors are: ALAS1, ETS1, ZFAND5, PCLAF

[0038] RS4 cells were treated with 100 nM AR4 and 5 μM proteasome inhibitor for 12 h, and the cells were collected and the total protein was extracted. Then, Western Blot detection was performed with four antibodies for ALAS1, ETS1, ZFAND5, and PCLAF. The results are shown in Figure 2 .

[0039] The results showed that except for ALAS1, the other three proteins were degraded, and the addition of MG132 blocked the degradation trend, further indicating that ETS1, ZFAND5, and PCLAF may be the target proteins of compound AR4.

Claims

1. A class of artemisinin derivatives, characterized in that: The derivative has the following general formula: ; In the formula, n is a natural number, n=1, 2, 3, 4.

2. Use of the artemisinin derivatives as claimed in claim 1 in the preparation of anti-tumor drugs.

3. The use according to claim 2, characterized in that: The tumor is a blood tumor.